A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 in Patients With Relapsing Forms of Multiple Sclerosis.
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 19 Jan 2012 Actual patient number (2417) added as reported by ClinicalTrials.gov.
- 19 Jan 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 19 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.